These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32486991)

  • 1. [Abuse deterrent drug formulations for opioids].
    Matter M; Mühlebach S; Puchkov M; Huwyler J
    Ther Umsch; 2020; 77(1):24-28. PubMed ID: 32486991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The opioid crisis: a 21st century pain.
    Walker G
    Drugs Today (Barc); 2018 Apr; 54(4):283-286. PubMed ID: 29869649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse-deterrent Opioid Formulations.
    Litman RS; Pagán OH; Cicero TJ
    Anesthesiology; 2018 May; 128(5):1015-1026. PubMed ID: 29252508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abuse-deterrent opioids.
    Med Lett Drugs Ther; 2017 Jun; 59(1522):95-96. PubMed ID: 28609421
    [No Abstract]   [Full Text] [Related]  

  • 7. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?
    Lourenço LM; Matthews M; Jamison RN
    Expert Opin Drug Deliv; 2013 Feb; 10(2):229-40. PubMed ID: 23252692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
    Lee YH; Brown DL; Chen HY
    Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders.
    Pergolizzi JV; Taylor R; LeQuang JA; Raffa RB
    Expert Opin Drug Deliv; 2018 Jun; 15(6):567-576. PubMed ID: 29739241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure.
    Roland CL; Setnik B; Brown DA
    Postgrad Med; 2017 Jan; 129(1):12-21. PubMed ID: 27960575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?
    Schneider JP; Matthews M; Jamison RN
    CNS Drugs; 2010 Oct; 24(10):805-10. PubMed ID: 20839893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
    Salwan AJ; Hagemeier NE; Harirforoosh S
    Clin Drug Investig; 2018 Jul; 38(7):573-577. PubMed ID: 29651781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations.
    Turk DC; O'Connor AB; Dworkin RH; Chaudhry A; Katz NP; Adams EH; Brownstein JS; Comer SD; Dart R; Dasgupta N; Denisco RA; Klein M; Leiderman DB; Lubran R; Rappaport BA; Zacny JP; Ahdieh H; Burke LB; Cowan P; Jacobs P; Malamut R; Markman J; Michna E; Palmer P; Peirce-Sandner S; Potter JS; Raja SN; Rauschkolb C; Roland CL; Webster LR; Weiss RD; Wolf K
    Pain; 2012 Oct; 153(10):1997-2008. PubMed ID: 22770841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the abuse potential of opioids and abuse-deterrent -opioid formulations: A review of clinical study methodology.
    Setnik B; Schoedel KA; Levy-Cooperman N; Shram M; Pixton GC; Roland CL
    J Opioid Manag; 2017; 13(6):485-523. PubMed ID: 29308594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations.
    Degenhardt L; Larance B; Peacock A; Farrell M
    Lancet Psychiatry; 2015 Nov; 2(11):957-9. PubMed ID: 26544739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.